Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2020-01-18 Director's Dealing
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-01-18 English
PRIMARY DOCUMENT
Director's Dealing
2020-01-18 English
PRIMARY DOCUMENT
Director's Dealing
2020-01-18 English
PRIMARY DOCUMENT
Director's Dealing
2020-01-18 English
Delisting Announcement 2019
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text specifically discusses a notice of delisting from Nasdaq due to non-compliance with listing standards, including stockholders' equity and bid price requirements. The document is not a full financial report but an official announcement of a significant event affecting the company's stock listing status. Therefore, it fits the category of a Delisting Announcement (DLST). The document length is about 4940 characters, which is sufficient to contain substantive information rather than just a brief notice. Hence, the classification is DLST with high confidence.
2019-11-26 English
Earnings Release 2019
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing financial results for the three and nine months ended September 30, 2019. The document includes a reference to the press release as an exhibit and states that the information is furnished and not filed for certain legal purposes. The document does not contain the actual financial statements or detailed financial data but rather announces the release of financial results and provides a business update. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. The document length is 4203 characters, which is relatively short and consistent with an earnings release announcement rather than a full interim or annual report. Therefore, the correct classification is ER with high confidence.
2019-11-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.